EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation

Hristian Hinkov iD, Sara Yousefzada, Isabell A Just iD, Christoph Klein, Evgenij Potapov, Santiago Garcia, Dhairya Patel iD, Lauren S Ranard iD, Arseniy Goncharov, Dean J Kereiakes iD, Raj R Makkar, Torsten P Vahl und 2 weitere

Artificial Organs · 2026

DOI: 10.1111/aor.70226 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Artificial Organs, 2026. Verfasst von Hristian Hinkov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Heart-Assist Devices, Postoperative Complications, Transcatheter Aortic Valve Replacement. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aortic regurgitation (AR) is a frequent and clinically relevant complication in patients with left ventricular assist devices (LVAD), impairing circulatory support and worsening outcomes. Surgical aortic valve replacement often carries prohibitive risk in this population, while conventional transcatheter aortic valve replacement (TAVR) is limited by the lack of annular calcification. The JenaValve Trilogy is the first transfemoral TAVR system with regulatory approval for AR. Evidence on its use in LVAD patients remains scarce.

Methods

We conducted a retrospective multicenter registry of LVAD recipients undergoing JenaValve Trilogy implantation for pure AR between 2020 and 2026 at five high‐volume centers in Germany and the United States. Patient characteristics, procedural details, and outcomes were analyzed. The primary endpoint was device success according to Valve Academic Research Consortium‐3 (VARC‐3) criteria at 30 days. Secondary endpoints included peri‐procedural complications, mortality, and device‐related reinterventions at follow‐up.

Results

Thirty patients (median age 66 years, 36.7% female, median LVAD support time: four years) were included. One patient did not meet criteria for technical success, and one experienced a fatal hemorrhagic stroke on postoperative day 2, rendering device success 93.3% (28/30). 30‐day mortality was 3.3% (1/30). At a median follow‐up of 273 days (IQR 30–491), survival was 93.3% (28/30).

Conclusion

This first multicenter experience demonstrates that JenaValve Trilogy provides a feasible and safe treatment option for clinically significant AR in LVAD patients at prohibitive surgical risk, with high device success and favorable short‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve InsufficiencyHeart-Assist DevicesPostoperative ComplicationsTranscatheter Aortic Valve ReplacementAgedFemaleHumansMaleAortic ValveGermanyRegistriesRetrospective StudiesTreatment OutcomeUnited States

Stichwörter der Autor:innen

JenaValve trilogyaortic regurgitationleft ventricular assist devicetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Structural Heart Interventions Program (SHIP), Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
  • Department of General and Interventional Cardiology and Angiology, Heart and Diabetes Center NRW, Ruhr University, Bad Oeynhausen, Germany.
  • Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.

ORCID-Profile: Hristian Hinkov, Isabell A Just, Dhairya Patel, Lauren S Ranard, Dean J Kereiakes, Axel Unbehaun

Zitieren

APA

Hinkov, H., Yousefzada, S., Just, I. A., Klein, C., Potapov, E., Garcia, S., Patel, D., Ranard, L. S., Goncharov, A., Kereiakes, D. J., Makkar, R. R., Vahl, T. P., Rudolph, T. K., & Unbehaun, A. (2026). Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation. Artificial Organs. https://doi.org/10.1111/aor.70226

Vancouver

Hinkov H, Yousefzada S, Just IA, Klein C, Potapov E, Garcia S, et al. Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation. Artificial Organs. 2026. doi:10.1111/aor.70226

BibTeX
@article{Hinkov2026,
  author = {Hinkov, Hristian and Yousefzada, Sara and Just, Isabell A and Klein, Christoph and Potapov, Evgenij and Garcia, Santiago and Patel, Dhairya and Ranard, Lauren S and Goncharov, Arseniy and Kereiakes, Dean J and Makkar, Raj R and Vahl, Torsten P and Rudolph, Tanja K and Unbehaun, Axel},
  title = {Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation},
  journal = {Artificial Organs},
  year = {2026},
  doi = {10.1111/aor.70226}
}
Kostenlos starten →